CEO: Steven J. Mento

Advent Contact: Shahzad Malik

EmricasanTM, a caspase inhibitor for liver diseases

The founding team of Conatus re-acquired EmricasanTM, a caspase inhibitor for reducing apoptosis and inflammation in the treatment of liver diseases. EmricasanTM is a hepatoprotectant arresting the rate of deterioration of liver function. It is in several Phase II clinical studies for a number of liver diseases.

Advent invested in the Series A in 2006. Conatus listed on NASDAQ in 2013 (NASDAQ:CNAT).

Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan